{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:05:13Z","timestamp":1773097513412,"version":"3.50.1"},"publisher-location":"Cham","reference-count":200,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031121838","type":"print"},{"value":"9783031121845","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/7854_2021_267","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:50:22Z","timestamp":1642153822000},"page":"287-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Psychedelics as Novel Therapeutics in Alzheimer\u2019s Disease: Rationale and Potential Mechanisms"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-1644","authenticated-orcid":false,"given":"Albert","family":"Garcia-Romeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"issue":"2","key":"267_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 34(2):155\u2013166","journal-title":"J Psychopharmacol"},{"issue":"3","key":"267_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","author":"Alzheimer\u2019s Association","year":"2021","unstructured":"Alzheimer\u2019s Association (2021) Alzheimer\u2019s disease facts and figures. Alzheimers Dement 17(3):327\u2013406. https:\/\/doi.org\/10.1002\/alz.12328","journal-title":"Alzheimers Dement"},{"key":"267_CR3","doi-asserted-by":"publisher","unstructured":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100538","DOI":"10.1016\/j.eclinm.2020.100538"},{"issue":"3","key":"267_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.nbd.2008.05.012","volume":"31","author":"S Arancibia","year":"2008","unstructured":"Arancibia S, Silhol M, Mouli\u00e8re F, Meffre J, H\u00f6llinger I, Maurice T, Tapia-Arancibia L (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31(3):316\u2013326. https:\/\/doi.org\/10.1016\/j.nbd.2008.05.012","journal-title":"Neurobiol Dis"},{"issue":"9","key":"267_CR5","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1111\/ene.15007","volume":"28","author":"S Ayton","year":"2021","unstructured":"Ayton S (2021) Brain volume loss due to donanemab. Eur J Neurol 28(9):e67\u2013e68. https:\/\/doi.org\/10.1111\/ene.15007","journal-title":"Eur J Neurol"},{"key":"267_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neubiorev.2016.02.008","volume":"64","author":"S Aznar","year":"2016","unstructured":"Aznar S, Hervig ME-S (2016) The 5-HT2A serotonin receptor in executive function: implications for neuropsychiatric and neurodegenerative diseases. Neurosci Biobehav Rev 64:63\u201382. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.02.008","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"267_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/hbm.22248","volume":"35","author":"MLF Balthazar","year":"2014","unstructured":"Balthazar MLF, Pereira FRS, Lopes TM, da Silva EL, Coan AC, Campos BM, Duncan NW, Stella F, Northoff G, Damasceno BP, Cendes F (2014) Neuropsychiatric symptoms in Alzheimer\u2019s disease are related to functional connectivity alterations in the salience network. Hum Brain Mapp 35(4):1237\u20131246. https:\/\/doi.org\/10.1002\/hbm.22248","journal-title":"Hum Brain Mapp"},{"issue":"7","key":"267_CR8","doi-asserted-by":"publisher","first-page":"Article 7","DOI":"10.3310\/hta17070","volume":"17","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Hellier J, Romer R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Livingston G, Lawton C, McCrae N, Moniz-Cook E, Murray J, Nurock J, Orrell M, O\u2019Brien J et al (2013) Study of the use of antidepressants for depression in dementia: the HTA -SADD trial \u2013 a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 17(7):Article 7. http:\/\/www.hta.ac.uk\/research\/HTAjournal.shtml","journal-title":"Health Technol Assess"},{"issue":"1","key":"267_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/gps.5418","volume":"36","author":"LCP Banning","year":"2021","unstructured":"Banning LCP, Ramakers IHGB, Rosenberg PB, Lyketsos CG, Leoutsakos J-MS (2021) Alzheimer\u2019s disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment, and Alzheimer\u2019s disease dementia. Int J Geriatr Psychiatry 36(1):224\u2013234. https:\/\/doi.org\/10.1002\/gps.5418","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"267_CR10","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","volume":"235","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology 235(10):2915\u20132927. https:\/\/doi.org\/10.1007\/s00213-018-4981-x","journal-title":"Psychopharmacology"},{"issue":"1","key":"267_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR (2020a) Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 10(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-020-59282-y","journal-title":"Sci Rep"},{"key":"267_CR12","doi-asserted-by":"publisher","first-page":"116980","DOI":"10.1016\/j.neuroimage.2020.116980","volume":"218","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN (2020b) Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage 218:116980. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.116980","journal-title":"NeuroImage"},{"issue":"9","key":"267_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367(9):795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753","journal-title":"N Engl J Med"},{"issue":"10","key":"267_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 86(10):792\u2013800. https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.019","journal-title":"Biol Psychiatry"},{"issue":"4","key":"267_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS (2014) Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505\u2013508. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5847","journal-title":"JAMA Neurol"},{"issue":"3","key":"267_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289\u2013299","journal-title":"J Psychopharmacol"},{"key":"267_CR17","doi-asserted-by":"publisher","unstructured":"Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE (2018) Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol 9. https:\/\/doi.org\/10.3389\/fphar.2018.00100","DOI":"10.3389\/fphar.2018.00100"},{"issue":"8","key":"267_CR18","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/sj.npp.1301584","volume":"33","author":"V Boulougouris","year":"2008","unstructured":"Boulougouris V, Glennon JC, Robbins TW (2008) Dissociable effects of selective 5-HT 2A and 5-HT 2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33(8):2007\u20132019. https:\/\/doi.org\/10.1038\/sj.npp.1301584","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"267_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-013-3167-9","volume":"230","author":"JC Bouso","year":"2013","unstructured":"Bouso JC, F\u00e1bregas JM, Antonijoan RM, Rodr\u00edguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology 230(3):415\u2013424. https:\/\/doi.org\/10.1007\/s00213-013-3167-9","journal-title":"Psychopharmacology"},{"issue":"4","key":"267_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259. https:\/\/doi.org\/10.1007\/BF00308809","journal-title":"Acta Neuropathol"},{"issue":"338","key":"267_CR21","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TLS, Ances BM (2016) Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med 8(338):338ra66. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2362","journal-title":"Sci Transl Med"},{"issue":"34","key":"267_CR22","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1523\/JNEUROSCI.2177-05.2005","volume":"25","author":"RL Buckner","year":"2005","unstructured":"Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer\u2019s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25(34):7709\u20137717. https:\/\/doi.org\/10.1523\/JNEUROSCI.2177-05.2005","journal-title":"J Neurosci"},{"issue":"1","key":"267_CR23","first-page":"77","volume":"2","author":"M Butzlaff","year":"2016","unstructured":"Butzlaff M, Ponimaskin E (2016) The role of serotonin receptors in Alzheimer\u2019s disease. Opera Med Physiol 2(1):77\u201386","journal-title":"Opera Med Physiol"},{"issue":"3","key":"267_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/acel.12057","volume":"12","author":"A Caccamo","year":"2013","unstructured":"Caccamo A, Magr\u00ec A, Medina DX, Wisely EV, L\u00f3pez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: implications for Alzheimer\u2019s disease and other tauopathies. Aging Cell 12(3):370\u2013380. https:\/\/doi.org\/10.1111\/acel.12057","journal-title":"Aging Cell"},{"issue":"24","key":"267_CR25","doi-asserted-by":"publisher","first-page":"14368","DOI":"10.1073\/pnas.2336098100","volume":"100","author":"M Cammalleri","year":"2003","unstructured":"Cammalleri M, L\u00fctjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (2003) Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc Natl Acad Sci 100(24):14368\u201314373. https:\/\/doi.org\/10.1073\/pnas.2336098100","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"267_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","volume":"200","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200(3):238\u2013244. https:\/\/doi.org\/10.1192\/bjp.bp.111.103309","journal-title":"Br J Psychiatry"},{"issue":"7","key":"267_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"267_CR28","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci Rep 7(1):13187. https:\/\/doi.org\/10.1038\/s41598-017-13282-7","journal-title":"Sci Rep"},{"issue":"15","key":"267_CR29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411","journal-title":"N Engl J Med"},{"issue":"10","key":"267_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1162\/089892905774597191","volume":"17","author":"OL Carter","year":"2005","unstructured":"Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17(10):1497\u20131508. https:\/\/doi.org\/10.1162\/089892905774597191","journal-title":"J Cogn Neurosci"},{"issue":"4","key":"267_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481\u2013491. https:\/\/doi.org\/10.1007\/s00221-013-3579-0","journal-title":"Exp Brain Res"},{"issue":"4","key":"267_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/mp.2017.241","volume":"23","author":"L Cavalleri","year":"2018","unstructured":"Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, Collo G (2018) Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. Mol Psychiatry 23(4):812\u2013823. https:\/\/doi.org\/10.1038\/mp.2017.241","journal-title":"Mol Psychiatry"},{"key":"267_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2019.03.050","volume":"704","author":"S Chakraborty","year":"2019","unstructured":"Chakraborty S, Lennon JC, Malkaram SA, Zeng Y, Fisher DW, Dong H (2019) Serotonergic system, cognition, and BPSD in Alzheimer\u2019s disease. Neurosci Lett 704:36\u201344. https:\/\/doi.org\/10.1016\/j.neulet.2019.03.050","journal-title":"Neurosci Lett"},{"issue":"10","key":"267_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"M-K Chen","year":"2018","unstructured":"Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH (2018) Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol 75(10):1215. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1836","journal-title":"JAMA Neurol"},{"key":"267_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbi.2013.04.001","volume":"32","author":"A Ciaramella","year":"2013","unstructured":"Ciaramella A, Salani F, Bizzoni F, Orfei MD, Langella R, Angelucci F, Spalletta G, Taddei AR, Caltagirone C, Boss\u00f9 P (2013) The stimulation of dendritic cells by amyloid beta 1\u201342 reduces BDNF production in Alzheimer\u2019s disease patients. Brain Behav Immun 32:29\u201332. https:\/\/doi.org\/10.1016\/j.bbi.2013.04.001","journal-title":"Brain Behav Immun"},{"issue":"5","key":"267_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat 78(5):481\u2013489","journal-title":"JAMA Psychiat"},{"issue":"11","key":"267_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/nn1146","volume":"6","author":"DJ-F de Quervain","year":"2003","unstructured":"de Quervain DJ-F, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C, Nitsch RM, Papassotiropoulos A (2003) A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci 6(11):1141\u20131142. https:\/\/doi.org\/10.1038\/nn1146","journal-title":"Nat Neurosci"},{"issue":"1","key":"267_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11065-014-9249-6","volume":"24","author":"EL Dennis","year":"2014","unstructured":"Dennis EL, Thompson PM (2014) Functional brain connectivity using fMRI in aging and Alzheimer\u2019s disease. Neuropsychol Rev 24(1):49\u201362. https:\/\/doi.org\/10.1007\/s11065-014-9249-6","journal-title":"Neuropsychol Rev"},{"issue":"8","key":"267_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/13543784.2021.1948010","volume":"30","author":"SA Doggrell","year":"2021","unstructured":"Doggrell SA (2021) Still grasping at straws: donanemab in Alzheimer\u2019s disease. Expert Opin Investig Drugs 30(8):797\u2013801. https:\/\/doi.org\/10.1080\/13543784.2021.1948010","journal-title":"Expert Opin Investig Drugs"},{"key":"267_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2020.11.013","volume":"42","author":"LL Donovan","year":"2021","unstructured":"Donovan LL, Johansen JV, Ros NF, Jaberi E, Linnet K, Johansen SS, Ozenne B, Issazadeh-Navikas S, Hansen HD, Knudsen GM (2021) Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. Eur Neuropsychopharmacol 42:1\u201311. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.11.013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"267_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1212\/WNL.0b013e3181e62124","volume":"75","author":"VM Dotson","year":"2010","unstructured":"Dotson VM, Beydoun MA, Zonderman AB (2010) Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75(1):27\u201334. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e62124","journal-title":"Neurology"},{"issue":"6","key":"267_CR42","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13(6):614\u2013629. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0","journal-title":"Lancet Neurol"},{"issue":"10","key":"267_CR43","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1523\/JNEUROSCI.16-10-03123.1996","volume":"16","author":"FF Eide","year":"1996","unstructured":"Eide FF, Vining ER, Eide BL, Zang K, Wang X-Y, Reichardt LF (1996) Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 16(10):3123\u20133129. https:\/\/doi.org\/10.1523\/JNEUROSCI.16-10-03123.1996","journal-title":"J Neurosci"},{"issue":"5","key":"267_CR44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","volume":"138","author":"D Erritzoe","year":"2018","unstructured":"Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 138(5):368\u2013378. https:\/\/doi.org\/10.1111\/acps.12904","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"267_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"N Family","year":"2020","unstructured":"Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2020) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841\u2013853. https:\/\/doi.org\/10.1007\/s00213-019-05417-7","journal-title":"Psychopharmacology"},{"issue":"4","key":"267_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 30(4):363\u2013375. https:\/\/doi.org\/10.1080\/09540261.2018.1481827","journal-title":"Int Rev Psychiatry"},{"key":"267_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbr.2014.06.025","volume":"277","author":"LR Frick","year":"2015","unstructured":"Frick LR, Bernardez-Vidal M, Hocht C, Zanutto BS, Rapanelli M (2015) Dual role of serotonin in the acquisition and extinction of reward-driven learning: involvement of 5-HT1A, 5-HT2A and 5-HT3 receptors. Behav Brain Res 277:193\u2013203. https:\/\/doi.org\/10.1016\/j.bbr.2014.06.025","journal-title":"Behav Brain Res"},{"issue":"9","key":"267_CR48","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1017\/S1461145711001441","volume":"15","author":"A Furr","year":"2012","unstructured":"Furr A, Lapiz-Bluhm MD, Morilak DA (2012) 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol 15(9):1295\u20131305. https:\/\/doi.org\/10.1017\/S1461145711001441","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"267_CR49","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1177\/0269881120936486","volume":"34","author":"NL Galv\u00e3o-Coelho","year":"2020","unstructured":"Galv\u00e3o-Coelho NL, de Menezes Galv\u00e3o AC, de Almeida RN, Palhano-Fontes F, Campos Braga I, Lob\u00e3o Soares B, Maia-de-Oliveira JP, Perkins D, Sarris J, de Araujo DB (2020) Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol 34(10):1125\u20131133","journal-title":"J Psychopharmacol"},{"issue":"3","key":"267_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7(3):157\u2013164","journal-title":"Curr Drug Abuse Rev"},{"issue":"4","key":"267_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","volume":"24","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH (2016) Clinical applications of hallucinogens: a review. Exp Clin Psychopharmacol 24(4):229","journal-title":"Exp Clin Psychopharmacol"},{"issue":"6","key":"267_CR52","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1038\/cddis.2011.50","volume":"2","author":"CJ Garwood","year":"2011","unstructured":"Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of a \u03b2-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2(6):e167\u2013e167","journal-title":"Cell Death Dis"},{"issue":"7","key":"267_CR53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513","journal-title":"J Nerv Ment Dis"},{"issue":"9","key":"267_CR54","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jagp.2019.03.008","volume":"27","author":"DR George","year":"2019","unstructured":"George DR, Hanson R (2019) Imagining a role for psychedelics in dementia care. Am J Geriatr Psychiatry 27(9):1028\u20131030. https:\/\/doi.org\/10.1016\/j.jagp.2019.03.008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"267_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 53(3):439\u2013452. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.008","journal-title":"Neuron"},{"issue":"3","key":"267_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME (2021) New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol 20(3):222\u2013234. https:\/\/doi.org\/10.1016\/S1474-4422(20)30440-3","journal-title":"Lancet Neurol"},{"issue":"6","key":"267_CR57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22(6):621\u2013632","journal-title":"J Psychopharmacol"},{"issue":"12","key":"267_CR59","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"issue":"1","key":"267_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 32(1):49\u201369","journal-title":"J Psychopharmacol"},{"issue":"1","key":"267_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1):71. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116","journal-title":"Arch Gen Psychiatry"},{"key":"267_CR62","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000467984","volume":"8","author":"S Grof","year":"1973","unstructured":"Grof S, Goodman LE, Richards WA, Kurland AA (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8:129\u2013144. https:\/\/doi.org\/10.1159\/000467984","journal-title":"Int Pharmacopsychiatry"},{"issue":"9","key":"267_CR63","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.biopsych.2011.06.019","volume":"71","author":"M Grothe","year":"2012","unstructured":"Grothe M, Heinsen H, Teipel SJ (2012) Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer\u2019s disease. Biol Psychiatry 71(9):805\u2013813. https:\/\/doi.org\/10.1016\/j.biopsych.2011.06.019","journal-title":"Biol Psychiatry"},{"issue":"3","key":"267_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.bbadis.2011.07.008","volume":"1822","author":"A Hafkemeijer","year":"2012","unstructured":"Hafkemeijer A, van der Grond J, Rombouts SARB (2012) Imaging the default mode network in aging and dementia. Biochim Biophys Acta 1822(3):431\u2013441. https:\/\/doi.org\/10.1016\/j.bbadis.2011.07.008","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"267_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00213-003-1687-4","volume":"172","author":"JA Harvey","year":"2004","unstructured":"Harvey JA, Quinn JL, Liu R, Aloyo VJ, Romano AG (2004) Selective remodeling of rabbit frontal cortex: relationship between 5-HT2A receptor density and associative learning. Psychopharmacology 172(4):435\u2013442. https:\/\/doi.org\/10.1007\/s00213-003-1687-4","journal-title":"Psychopharmacology"},{"issue":"12","key":"267_CR66","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.neurobiolaging.2007.04.011","volume":"29","author":"SG Hasselbalch","year":"2008","unstructured":"Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM (2008) Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 29(12):1830\u20131838. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.04.011","journal-title":"Neurobiol Aging"},{"issue":"7","key":"267_CR67","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/hbm.22414","volume":"35","author":"X He","year":"2014","unstructured":"He X, Qin W, Liu Y, Zhang X, Duan Y, Song J, Li K, Jiang T, Yu C (2014) Abnormal salience network in normal aging and in amnestic mild cognitive impairment and Alzheimer\u2019s disease. Hum Brain Mapp 35(7):3446\u20133464. https:\/\/doi.org\/10.1002\/hbm.22414","journal-title":"Hum Brain Mapp"},{"key":"267_CR68","volume-title":"International population reports, P95\/16-1, An aging world: 2015, U.S. Census Bureau","author":"W He","year":"2016","unstructured":"He W, Goodkind D, Kowal P (2016) International population reports, P95\/16-1, An aging world: 2015, U.S. Census Bureau. U.S. Government Publishing Office, Washington, DC"},{"issue":"3","key":"267_CR69","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00213-020-05756-w","volume":"238","author":"CJ Healy","year":"2021","unstructured":"Healy CJ (2021) The acute effects of classic psychedelics on memory in humans. Psychopharmacology 238(3):639\u2013653. https:\/\/doi.org\/10.1007\/s00213-020-05756-w","journal-title":"Psychopharmacology"},{"key":"267_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yfrne.2015.12.001","volume":"41","author":"J Herbert","year":"2016","unstructured":"Herbert J, Lucassen PJ (2016) Depression as a risk factor for Alzheimer\u2019s disease: genes, steroids, cytokines and neurogenesis \u2013 what do we need to know? Front Neuroendocrinol 41:153\u2013171. https:\/\/doi.org\/10.1016\/j.yfrne.2015.12.001","journal-title":"Front Neuroendocrinol"},{"issue":"2","key":"267_CR71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","volume":"33","author":"CA Hoeffer","year":"2010","unstructured":"Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33(2):67\u201375. https:\/\/doi.org\/10.1016\/j.tins.2009.11.003","journal-title":"Trends Neurosci"},{"issue":"4","key":"267_CR72","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3233\/JAD-2010-100117","volume":"20","author":"P Holm","year":"2010","unstructured":"Holm P, Ettrup A, Klein AB, Santini MA, El-Sayed M, Elvang AB, Stensb\u00f8l TB, Mikkelsen JD, Knudsen GM, Aznar S (2010) Plaque deposition dependent decrease in 5-HT 2A serotonin receptor in A\u03b2PPswe\/PS1dE9 amyloid overexpressing mice. J Alzheimers Dis 20(4):1201\u20131213. https:\/\/doi.org\/10.3233\/JAD-2010-100117","journal-title":"J Alzheimers Dis"},{"key":"267_CR73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","volume":"41","author":"NRPW Hutten","year":"2020","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Feilding A, Ramaekers JG, Kuypers KPC (2020) Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study. Eur Neuropsychopharmacol 41:81\u201391. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.10.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"267_CR74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"NRPW Hutten","year":"2021","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Varghese N, Eckert A, Feilding A, Ramaekers JG, Kuypers KPC (2021) Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci 4(2):461\u2013466. https:\/\/doi.org\/10.1021\/acsptsci.0c00099","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"267_CR75","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-160979","volume":"56","author":"Z Ismail","year":"2017","unstructured":"Ismail Z, Ag\u00fcera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanct\u00f4t KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C, for the N. P. I. A. of the I. S. of to A. A. R. and T. (NPS-P. of ISTAART) (2017) The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis 56(3):929\u2013938. https:\/\/doi.org\/10.3233\/JAD-160979","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"267_CR76","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack Jr","year":"2019","unstructured":"Jack CR Jr, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, Graff-Radford J, Jones DT, Ferman TJ, Boeve BF (2019) The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain 142(10):3230\u20133242","journal-title":"Brain"},{"issue":"2","key":"267_CR77","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/00223980.1955.9916194","volume":"39","author":"ME Jarvik","year":"1955","unstructured":"Jarvik ME, Abramson HA, Hirsch MW (1955) Lysergic acid diethylamide (LSD-25): VI. Effect upon recall and recognition of various stimuli. J Psychol 39(2):443\u2013454. https:\/\/doi.org\/10.1080\/00223980.1955.9916194","journal-title":"J Psychol"},{"issue":"3","key":"267_CR78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1385\/MN:34:3:205","volume":"34","author":"J Jaworski","year":"2006","unstructured":"Jaworski J, Sheng M (2006) The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol 34(3):205\u2013219. https:\/\/doi.org\/10.1385\/MN:34:3:205","journal-title":"Mol Neurobiol"},{"issue":"4","key":"267_CR79","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0269881120959614","volume":"35","author":"OH Jefsen","year":"2021","unstructured":"Jefsen OH, Elfving B, Wegener G, M\u00fcller HK (2021) Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol 35(4):483\u2013493. https:\/\/doi.org\/10.1177\/0269881120959614","journal-title":"J Psychopharmacol"},{"issue":"6","key":"267_CR80","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"issue":"11","key":"267_CR81","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992","journal-title":"J Psychopharmacol"},{"key":"267_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology 142:143\u2013166","journal-title":"Neuropharmacology"},{"issue":"46","key":"267_CR83","doi-asserted-by":"publisher","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","volume":"32","author":"RL Joie","year":"2012","unstructured":"Joie RL, Perrotin A, Barr\u00e9 L, Hommet C, M\u00e9zenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, Sayette VL, Eustache F, Desgranges B, Ch\u00e9telat G (2012) Region-specific hierarchy between atrophy, hypometabolism, and \u03b2-amyloid (A\u03b2) load in Alzheimer\u2019s disease dementia. J Neurosci 32(46):16265\u201316273. https:\/\/doi.org\/10.1523\/JNEUROSCI.2170-12.2012","journal-title":"J Neurosci"},{"issue":"2","key":"267_CR84","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76(2):185\u2013205. https:\/\/doi.org\/10.1002\/ana.24188","journal-title":"Ann Neurol"},{"issue":"9","key":"267_CR85","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, Strooper BD (2011) The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698\u2013712. https:\/\/doi.org\/10.1038\/nrd3505","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"267_CR86","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/gps.2550","volume":"26","author":"K Karttunen","year":"2011","unstructured":"Karttunen K, Karppi P, Hiltunen A, Vanhanen M, V\u00e4lim\u00e4ki T, Martikainen J, Valtonen H, Sivenius J, Soininen H, Hartikainen S, Suhonen J, Pirttil\u00e4 T (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer\u2019s disease. Int J Geriatr Psychiatry 26(5):473\u2013482. https:\/\/doi.org\/10.1002\/gps.2550","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"267_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12877-016-0342-y","volume":"16","author":"LOJ Killin","year":"2016","unstructured":"Killin LOJ, Starr JM, Shiue IJ, Russ TC (2016) Environmental risk factors for dementia: a systematic review. BMC Geriatr 16(1):175. https:\/\/doi.org\/10.1186\/s12877-016-0342-y","journal-title":"BMC Geriatr"},{"issue":"7","key":"267_CR88","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneurol.2011.76","volume":"7","author":"SYH Kim","year":"2011","unstructured":"Kim SYH (2011) The ethics of informed consent in Alzheimer disease research. Nat Rev Neurol 7(7):410\u2013414. https:\/\/doi.org\/10.1038\/nrneurol.2011.76","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"267_CR89","first-page":"161P","volume":"45","author":"AR King","year":"1972","unstructured":"King AR, Martin IL, Seymour KA (1972) Reversal learning facilitated by a single injection of lysergic acid diethylamide (LSD 25) in the rat. Br J Pharmacol 45(1):161P\u2013162P","journal-title":"Br J Pharmacol"},{"key":"267_CR90","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia Transl Res Clin Interv 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimer\u2019s Dementia Transl Res Clin Interv"},{"key":"267_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fnagi.2017.00097","volume":"9","author":"BL Klaassens","year":"2017","unstructured":"Klaassens BL, van Gerven J, van der Grond J, de Vos F, M\u00f6ller C, Rombouts SA (2017) Diminished posterior precuneus connectivity with the default mode network differentiates normal aging from Alzheimer\u2019s disease. Front Aging Neurosci 9:97","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"267_CR92","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD (2021) Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 17(4):696\u2013701. https:\/\/doi.org\/10.1002\/alz.12213","journal-title":"Alzheimers Dement"},{"issue":"3","key":"267_CR93","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S et al (2019) Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet 51(3):414\u2013430. https:\/\/doi.org\/10.1038\/s41588-019-0358-2","journal-title":"Nat Genet"},{"issue":"3","key":"267_CR94","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00213-004-2077-2","volume":"179","author":"MK Lai","year":"2005","unstructured":"Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, Francis PT, Chen CP (2005) Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer\u2019s disease. Psychopharmacology 179(3):673\u2013677. https:\/\/doi.org\/10.1007\/s00213-004-2077-2","journal-title":"Psychopharmacology"},{"issue":"3","key":"267_CR95","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.trci.2017.07.001","volume":"3","author":"KL Lanct\u00f4t","year":"2017","unstructured":"Lanct\u00f4t KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B (2017) Neuropsychiatric signs and symptoms of Alzheimer\u2019s disease: new treatment paradigms. Alzheimer\u2019s Dementia Transl Res Clin Interv 3(3):440\u2013449. https:\/\/doi.org\/10.1016\/j.trci.2017.07.001","journal-title":"Alzheimer\u2019s Dementia Transl Res Clin Interv"},{"issue":"3","key":"267_CR96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00005053-196703000-00002","volume":"144","author":"RJ Langs","year":"1967","unstructured":"Langs RJ (1967) Stability of earliest memories under LSD-25 AND PLACEBO. J Nerv Ment Dis 144(3):171\u2013184","journal-title":"J Nerv Ment Dis"},{"issue":"2","key":"267_CR97","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3233\/JAD-150421","volume":"48","author":"J-MS Leoutsakos","year":"2015","unstructured":"Leoutsakos J-MS, Forrester SN, Lyketsos CG, Smith GS (2015) Latent classes of neuropsychiatric symptoms in NACC controls and conversion to mild cognitive impairment or dementia. J Alzheimers Dis 48(2):483\u2013493. https:\/\/doi.org\/10.3233\/JAD-150421","journal-title":"J Alzheimers Dis"},{"key":"267_CR98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuropharm.2014.11.025","volume":"91","author":"L-B Li","year":"2015","unstructured":"Li L-B, Zhang L, Sun Y-N, Han L-N, Wu Z-H, Zhang Q-J, Liu J (2015) Activation of serotonin2A receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. Neuropharmacology 91:23\u201333. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.025","journal-title":"Neuropharmacology"},{"key":"267_CR99","doi-asserted-by":"publisher","unstructured":"Lima da Cruz RV, Moulin TC, Petiz LL, Le\u00e3o RN (2018) A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Front Mol Neurosci 11. https:\/\/doi.org\/10.3389\/fnmol.2018.00312","DOI":"10.3389\/fnmol.2018.00312"},{"issue":"51","key":"267_CR100","doi-asserted-by":"publisher","first-page":"13805","DOI":"10.1523\/JNEUROSCI.4218-08.2008","volume":"28","author":"Y Liu","year":"2008","unstructured":"Liu Y, Yoo M-J, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 28(51):13805\u201313814. https:\/\/doi.org\/10.1523\/JNEUROSCI.4218-08.2008","journal-title":"J Neurosci"},{"issue":"11","key":"267_CR101","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170\u20133182. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022","journal-title":"Cell Rep"},{"issue":"12","key":"267_CR102","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288(12):1475. https:\/\/doi.org\/10.1001\/jama.288.12.1475","journal-title":"JAMA"},{"issue":"7","key":"267_CR103","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.JGP.0000221334.65330.55","volume":"14","author":"CG Lyketsos","year":"2006","unstructured":"Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian DA, Yaffe K (2006) Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer Disease. Am J Geriatr Psychiatry 14(7):561\u2013573. https:\/\/doi.org\/10.1097\/01.JGP.0000221334.65330.55","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"267_CR104","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS (2011) Neuropsychiatric symptoms in Alzheimer\u2019s disease. Alzheimers Dement 7(5):532\u2013539. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2410","journal-title":"Alzheimers Dement"},{"issue":"11","key":"267_CR105","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25(11):1453\u20131461","journal-title":"J Psychopharmacol"},{"key":"267_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"MK Madsen","year":"2020","unstructured":"Madsen MK, Fisher PM, Stenb\u00e6k DS, Kristiansen S, Burmester D, Lehel S, P\u00e1len\u00ed\u010dek T, Kucha\u0159 M, Svarer C, Ozenne B, Knudsen GM (2020) A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol 33:71\u201380. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.02.001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"267_CR107","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neurobiolaging.2010.03.023","volume":"33","author":"L Marner","year":"2012","unstructured":"Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baar\u00e9 WF, Knudsen GM, Hasselbalch SG (2012) Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer\u2019s disease: a combined [11C] DASB and [18F] altanserin-PET study. Neurobiol Aging 33(3):479\u2013487","journal-title":"Neurobiol Aging"},{"key":"267_CR108","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology 190:108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352","journal-title":"Neuropharmacology"},{"issue":"1","key":"267_CR109","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56(1):127\u2013129. https:\/\/doi.org\/10.1212\/WNL.56.1.127","journal-title":"Neurology"},{"issue":"12","key":"267_CR110","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","volume":"45","author":"NL Mason","year":"2020","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, Hutten NRPW, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020) Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology 45(12):2003\u20132011. https:\/\/doi.org\/10.1038\/s41386-020-0718-8","journal-title":"Neuropsychopharmacology"},{"key":"267_CR111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/bs.pmbts.2019.04.003","volume-title":"Progress in molecular biology and translational science","author":"AP Mecca","year":"2019","unstructured":"Mecca AP (2019) 1ciii - AD molecular: molecular imaging of Alzheimer\u2019s disease: PET imaging of neurotransmitter systems. In: Becker JT, Cohen AD (eds) Progress in molecular biology and translational science, vol vol 165. Academic Press, pp 139\u2013165. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.04.003"},{"key":"267_CR112","doi-asserted-by":"publisher","first-page":"e535816","DOI":"10.4061\/2011\/535816","volume":"2011","author":"K Mevel","year":"2011","unstructured":"Mevel K, Ch\u00e9telat G, Eustache F, Desgranges B (2011) The default mode network in healthy aging and Alzheimer\u2019s disease. Int J Alzheimers Dis 2011:e535816. https:\/\/doi.org\/10.4061\/2011\/535816","journal-title":"Int J Alzheimers Dis"},{"issue":"11","key":"267_CR113","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/j.1460-9568.2010.07460.x","volume":"32","author":"K Michaelsen","year":"2010","unstructured":"Michaelsen K, Zagrebelsky M, Berndt-Huch J, Polack M, Buschler A, Sendtner M, Korte M (2010) Neurotrophin receptors TrkB.T1 and p75NTR cooperate in modulating both functional and structural plasticity in mature hippocampal neurons. Eur J Neurosci 32(11):1854\u20131865. https:\/\/doi.org\/10.1111\/j.1460-9568.2010.07460.x","journal-title":"Eur J Neurosci"},{"issue":"2","key":"267_CR114","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40266-015-0239-z","volume":"32","author":"M Miguel-\u00c1lvarez","year":"2015","unstructured":"Miguel-\u00c1lvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, Lucia A (2015) Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer\u2019s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 32(2):139\u2013147","journal-title":"Drugs Aging"},{"issue":"12","key":"267_CR115","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nrn2738","volume":"10","author":"L Minichiello","year":"2009","unstructured":"Minichiello L (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10(12):850\u2013860. https:\/\/doi.org\/10.1038\/nrn2738","journal-title":"Nat Rev Neurosci"},{"issue":"18","key":"267_CR116","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"issue":"10","key":"267_CR117","doi-asserted-by":"publisher","first-page":"e75426","DOI":"10.1371\/journal.pone.0075426","volume":"8","author":"F Nau Jr","year":"2013","unstructured":"Nau F Jr, Yu B, Martin D, Nichols CD (2013) Serotonin 5-HT 2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo. PLoS One 8(10):e75426","journal-title":"PLoS One"},{"issue":"4","key":"267_CR118","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1532-5415.2011.03355.x","volume":"59","author":"JC Nelson","year":"2011","unstructured":"Nelson JC, Devanand DP (2011) A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 59(4):577\u2013585. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03355.x","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"267_CR119","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"issue":"10","key":"267_CR120","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols DE (2020) Psilocybin: from ancient magic to modern medicine. J Antibiot 73(10):679\u2013686. https:\/\/doi.org\/10.1038\/s41429-020-0311-8","journal-title":"J Antibiot"},{"issue":"5","key":"267_CR121","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0893-133X(01)00405-5","volume":"26","author":"CD Nichols","year":"2002","unstructured":"Nichols CD, Sanders-Bush E (2002) A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 26(5):634\u2013642. https:\/\/doi.org\/10.1016\/S0893-133X(01)00405-5","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"267_CR122","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0169-328X(03)00029-9","volume":"111","author":"CD Nichols","year":"2003","unstructured":"Nichols CD, Garcia EE, Sanders-Bush E (2003) Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Mol Brain Res 111(1):182\u2013188. https:\/\/doi.org\/10.1016\/S0169-328X(03)00029-9","journal-title":"Mol Brain Res"},{"issue":"7","key":"267_CR123","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol 32(7):756\u2013769. https:\/\/doi.org\/10.1177\/0269881118780612","journal-title":"J Psychopharmacol"},{"key":"267_CR124","doi-asserted-by":"publisher","first-page":"117906951880050","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci 12:1179069518800508. https:\/\/doi.org\/10.1177\/1179069518800508","journal-title":"J Exp Neurosci"},{"issue":"2","key":"267_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE (2021) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci 4(2):563\u2013567. https:\/\/doi.org\/10.1021\/acsptsci.0c00192","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"5","key":"267_CR126","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, O\u2019Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139(5):1551\u20131567. https:\/\/doi.org\/10.1093\/brain\/aww027","journal-title":"Brain"},{"key":"267_CR127","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","volume":"72","author":"T Ozben","year":"2019","unstructured":"Ozben T, Ozben S (2019) Neuro-inflammation and anti-inflammatory treatment options for Alzheimer\u2019s disease. Clin Biochem 72:87\u201389. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.001","journal-title":"Clin Biochem"},{"issue":"4","key":"267_CR128","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Os\u00f3rio FL, Sanches R, dos Santos RG, T\u00f3foli LF, Silveira GO, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galv\u00e3o-Coelho NL, Lob\u00e3o-Soares B et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655\u2013663. https:\/\/doi.org\/10.1017\/S0033291718001356","journal-title":"Psychol Med"},{"issue":"1","key":"267_CR129","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Sch\u00f6ll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O (2017) Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 8(1):1214. https:\/\/doi.org\/10.1038\/s41467-017-01150-x","journal-title":"Nat Commun"},{"issue":"12","key":"267_CR130","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop JJ, Mucke L (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 17(12):777\u2013792. https:\/\/doi.org\/10.1038\/nrn.2016.141","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"267_CR131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/ADR-190121","volume":"3","author":"L Pasquini","year":"2019","unstructured":"Pasquini L, Rahmani F, Maleki-Balajoo S, La Joie R, Zarei M, Sorg C, Drzezga A, Tahmasian M (2019) Medial temporal lobe disconnection and hyperexcitability across Alzheimer\u2019s disease stages. J Alzheimer\u2019s Dis Rep 3(1):103\u2013112. https:\/\/doi.org\/10.3233\/ADR-190121","journal-title":"J Alzheimer\u2019s Dis Rep"},{"issue":"6","key":"267_CR132","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/0269881120909409","volume":"34","author":"L Pasquini","year":"2020","unstructured":"Pasquini L, Palhano-Fontes F, Araujo DB (2020) Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol 34(6):623\u2013635. https:\/\/doi.org\/10.1177\/0269881120909409","journal-title":"J Psychopharmacol"},{"issue":"6","key":"267_CR133","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1471-4159.2005.03135.x","volume":"93","author":"S Peng","year":"2005","unstructured":"Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer\u2019s disease. J Neurochem 93(6):1412\u20131421. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03135.x","journal-title":"J Neurochem"},{"issue":"5","key":"267_CR134","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the cache county dementia progression study. Am J Psychiatr 172(5):460\u2013465. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14040480","journal-title":"Am J Psychiatr"},{"issue":"13","key":"267_CR135","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1017\/S0033291719002393","volume":"50","author":"T Pokorny","year":"2020","unstructured":"Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH (2020) LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med 50(13):2255\u20132264. https:\/\/doi.org\/10.1017\/S0033291719002393","journal-title":"Psychol Med"},{"issue":"2","key":"267_CR136","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, Seifritz E, Repov\u0161 G, Krystal JH, Murray JD, Anticevic A, Vollenweider FX (2020) Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry 88(2):197\u2013207. https:\/\/doi.org\/10.1016\/j.biopsych.2019.12.027","journal-title":"Biol Psychiatry"},{"issue":"48","key":"267_CR137","doi-asserted-by":"publisher","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","volume":"31","author":"D Putcha","year":"2011","unstructured":"Putcha D, Brickhouse M, O\u2019Keefe K, Sullivan C, Rentz D, Marshall G, Dickerson B, Sperling R (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer\u2019s disease signature regions in non-demented elderly adults. J Neurosci 31(48):17680\u201317688. https:\/\/doi.org\/10.1523\/JNEUROSCI.4740-11.2011","journal-title":"J Neurosci"},{"issue":"2","key":"267_CR138","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM (2021) A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int J Mol Sci 22(2):835. https:\/\/doi.org\/10.3390\/ijms22020835","journal-title":"Int J Mol Sci"},{"issue":"5","key":"267_CR139","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatr 177(5):391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","journal-title":"Am J Psychiatr"},{"issue":"02","key":"267_CR140","doi-asserted-by":"publisher","first-page":"24.432725","DOI":"10.1101\/2021.02.24.432725","volume":"2021","author":"MF Revenga","year":"2021","unstructured":"Revenga MF, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, Toneatti R, Sierra S, Wolstenholme JT, Beardsley PM, Huntley GW, Lu C, Gonz\u00e1lez-Maeso J (2021) Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice. BioRxiv 2021(02):24.432725. https:\/\/doi.org\/10.1101\/2021.02.24.432725","journal-title":"BioRxiv"},{"key":"267_CR141","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","volume":"94","author":"L Rice","year":"2017","unstructured":"Rice L, Bisdas S (2017) The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014a systematic review. Eur J Radiol 94:16\u201324. https:\/\/doi.org\/10.1016\/j.ejrad.2017.07.014","journal-title":"Eur J Radiol"},{"issue":"1","key":"267_CR142","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1212\/WNL.45.1.51","volume":"45","author":"JB Rich","year":"1995","unstructured":"Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer\u2019s disease. Neurology 45(1):51\u201355. https:\/\/doi.org\/10.1212\/WNL.45.1.51","journal-title":"Neurology"},{"issue":"1","key":"267_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.1977.10472020","volume":"9","author":"WA Richards","year":"1977","unstructured":"Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9(1):1\u201310","journal-title":"J Psychedelic Drugs"},{"issue":"3","key":"267_CR144","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00213-010-2004-7","volume":"212","author":"AG Romano","year":"2010","unstructured":"Romano AG, Quinn JL, Li L, Dave KD, Schindler EA, Aloyo VJ, Harvey JA (2010) Intrahippocampal LSD accelerates learning and desensitizes the 5-HT2A receptor in the rabbit, Romano et al. Psychopharmacology 212(3):441\u2013448. https:\/\/doi.org\/10.1007\/s00213-010-2004-7","journal-title":"Psychopharmacology"},{"key":"267_CR145","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974","journal-title":"Front Pharmacol"},{"issue":"2","key":"267_CR146","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","volume":"18","author":"PB Rosenberg","year":"2010","unstructured":"Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Drye LT (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18(2):136\u2013145. https:\/\/doi.org\/10.1097\/JGP.0b013e3181c796eb","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"267_CR147","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"issue":"8","key":"267_CR148","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jagp.2019.02.003","volume":"27","author":"M Ruthirakuhan","year":"2019","unstructured":"Ruthirakuhan M, Herrmann N, Vieira D, Gallagher D, Lanct\u00f4t KL (2019) The roles of apathy and depression in predicting Alzheimer disease: a longitudinal analysis in older adults with mild cognitive impairment. Am J Geriatr Psychiatry 27(8):873\u2013882. https:\/\/doi.org\/10.1016\/j.jagp.2019.02.003","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"267_CR149","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-neuro-070815-014015","volume":"39","author":"C Sala Frigerio","year":"2016","unstructured":"Sala Frigerio C, De Strooper B (2016) Alzheimer\u2019s disease mechanisms and emerging roads to novel therapeutics. Annu Rev Neurosci 39(1):57\u201379. https:\/\/doi.org\/10.1146\/annurev-neuro-070815-014015","journal-title":"Annu Rev Neurosci"},{"issue":"9","key":"267_CR150","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ijnp\/pyx036","volume":"20","author":"F Sampedro","year":"2017","unstructured":"Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Dom\u00ednguez-Clav\u00e9 E, Elices M, Luna LE, Crippa JAS, Hallak JEC, de Araujo DB, Friedlander P, Barker SA, \u00c1lvarez E, Soler J, Pascual JC, Feilding A, Riba J (2017) Assessing the psychedelic \u201cafter-glow\u201d in Ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int J Neuropsychopharmacol 20(9):698\u2013711. https:\/\/doi.org\/10.1093\/ijnp\/pyx036","journal-title":"Int J Neuropsychopharmacol"},{"key":"267_CR151","doi-asserted-by":"publisher","unstructured":"Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 62(10). https:\/\/doi.org\/10.1001\/archneur.62.10.1601","DOI":"10.1001\/archneur.62.10.1601"},{"issue":"1","key":"267_CR152","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC (2021) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics 18(1):534\u2013543. https:\/\/doi.org\/10.1007\/s13311-020-00962-y","journal-title":"Neurotherapeutics"},{"issue":"2","key":"267_CR153","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Y Schmid","year":"2018","unstructured":"Schmid Y, Liechti ME (2018) Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology 235(2):535\u2013545. https:\/\/doi.org\/10.1007\/s00213-017-4733-3","journal-title":"Psychopharmacology"},{"issue":"1","key":"267_CR154","doi-asserted-by":"publisher","first-page":"e15984","DOI":"10.1371\/journal.pone.0015984","volume":"6","author":"BH Schott","year":"2011","unstructured":"Schott BH, Seidenbecher CI, Richter S, W\u00fcstenberg T, Debska-Vielhaber G, Schubert H, Heinze H-J, Richardson-Klavehn A, D\u00fczel E (2011) Genetic variation of the serotonin 2a receptor affects hippocampal novelty processing in humans. PLoS One 6(1):e15984. https:\/\/doi.org\/10.1371\/journal.pone.0015984","journal-title":"PLoS One"},{"issue":"7","key":"267_CR155","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cercor\/bhs160","volume":"23","author":"GC Schwindt","year":"2013","unstructured":"Schwindt GC, Chaudhary S, Crane D, Ganda A, Masellis M, Grady CL, Stefanovic B, Black SE (2013) Modulation of the default-mode network between rest and task in Alzheimer\u2019s disease. Cereb Cortex 23(7):1685\u20131694. https:\/\/doi.org\/10.1093\/cercor\/bhs160","journal-title":"Cereb Cortex"},{"issue":"5594","key":"267_CR156","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298(5594):789\u2013791. https:\/\/doi.org\/10.1126\/science.1074069","journal-title":"Science"},{"issue":"1","key":"267_CR157","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011a) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189. https:\/\/doi.org\/10.1101\/cshperspect.a006189","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"267_CR158","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ajpath.2011.05.047","volume":"179","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Mielke ML, G\u00f3mez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT (2011b) Reactive glia not only associates with plaques but also parallels tangles in Alzheimer\u2019s disease. Am J Pathol 179(3):1373\u20131384. https:\/\/doi.org\/10.1016\/j.ajpath.2011.05.047","journal-title":"Am J Pathol"},{"issue":"12","key":"267_CR159","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1523\/JNEUROSCI.3335-10.2011","volume":"31","author":"C Sestieri","year":"2011","unstructured":"Sestieri C, Corbetta M, Romani GL, Shulman GL (2011) Episodic memory retrieval, parietal cortex, and the default mode network: functional and topographic analyses. J Neurosci 31(12):4407\u20134420. https:\/\/doi.org\/10.1523\/JNEUROSCI.3335-10.2011","journal-title":"J Neurosci"},{"issue":"7618","key":"267_CR160","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"267_CR161","doi-asserted-by":"publisher","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008","DOI":"10.1016\/j.neuron.2021.06.008"},{"issue":"6","key":"267_CR162","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00019442-200506000-00005","volume":"13","author":"I-S Shin","year":"2005","unstructured":"Shin I-S, Carter M, Masterman D, Fairbanks L, Cummings JL (2005) Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 13(6):469\u2013474. https:\/\/doi.org\/10.1097\/00019442-200506000-00005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"267_CR163","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10(1):24\u201335. https:\/\/doi.org\/10.1097\/00019442-200201000-00004","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"267_CR164","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","volume":"9","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Kometer M, Scheidegger M, Kr\u00e4henmann R, Huber T, Vollenweider FX (2019a) Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep 9(1):14914. https:\/\/doi.org\/10.1038\/s41598-019-50612-3","journal-title":"Sci Rep"},{"key":"267_CR165","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","volume":"196","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Scheidegger M, Kometer M, Vollenweider FX (2019b) Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage 196:207\u2013215. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.04.009","journal-title":"NeuroImage"},{"key":"267_CR166","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.nbd.2017.05.007","volume":"105","author":"GS Smith","year":"2017","unstructured":"Smith GS, Barrett FS, Joo JH, Nassery N, Savonenko A, Sodums DJ, Marano CM, Munro CA, Brandt J, Kraut MA, Zhou Y, Wong DF, Workman CI (2017) Molecular imaging of serotonin degeneration in mild cognitive impairment. Neurobiol Dis 105:33\u201341. https:\/\/doi.org\/10.1016\/j.nbd.2017.05.007","journal-title":"Neurobiol Dis"},{"issue":"2","key":"267_CR167","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1041610214001720","volume":"27","author":"M Soto","year":"2015","unstructured":"Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, Vellas B, Lyketsos CG, Rosenberg PB (2015) Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr 27(2):181\u2013197. https:\/\/doi.org\/10.1017\/S1041610214001720","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"267_CR168","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):280\u2013292. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003","journal-title":"Alzheimers Dement"},{"issue":"2","key":"267_CR169","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/gps.1858","volume":"23","author":"M Steinberg","year":"2008","unstructured":"Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JCS, Steffens DC, Tschanz JT (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23(2):170\u2013177. https:\/\/doi.org\/10.1002\/gps.1858","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"267_CR170","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.48.3.626","volume":"48","author":"WF Stewart","year":"1997","unstructured":"Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer\u2019s disease and duration of NSAID use. Neurology 48(3):626\u2013632. https:\/\/doi.org\/10.1212\/WNL.48.3.626","journal-title":"Neurology"},{"issue":"2","key":"267_CR171","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cortex.2005.11.002","volume":"44","author":"CL Stopford","year":"2008","unstructured":"Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer\u2019s disease. Cortex 44(2):185\u2013195. https:\/\/doi.org\/10.1016\/j.cortex.2005.11.002","journal-title":"Cortex"},{"issue":"5","key":"267_CR172","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/0022167817715966","volume":"57","author":"TC Swift","year":"2017","unstructured":"Swift TC, Belser AB, Agin-Liebes G, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S (2017) Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol 57(5):488\u2013519","journal-title":"J Humanist Psychol"},{"issue":"8","key":"267_CR173","doi-asserted-by":"publisher","first-page":"e106533","DOI":"10.1371\/journal.pone.0106533","volume":"9","author":"A Szabo","year":"2014","unstructured":"Szabo A, Kovacs A, Frecska E, Rajnavolgyi E (2014) Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One 9(8):e106533","journal-title":"PLoS One"},{"issue":"8","key":"267_CR174","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00005072-199708000-00011","volume":"56","author":"C-I Sze","year":"1997","unstructured":"Sze C-I, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56(8):933\u2013944. https:\/\/doi.org\/10.1097\/00005072-199708000-00011","journal-title":"J Neuropathol Exp Neurol"},{"key":"267_CR175","doi-asserted-by":"publisher","first-page":"e5320135","DOI":"10.1155\/2017\/5320135","volume":"2017","author":"L Tang","year":"2017","unstructured":"Tang L, Wang Y, Chen Y, Chen L, Zheng S, Bao M, Xiang J, Luo H, Li J, Li Y (2017) The association between 5HT2A T102C and behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease: a meta-analysis. Biomed Res Int 2017:e5320135. https:\/\/doi.org\/10.1155\/2017\/5320135","journal-title":"Biomed Res Int"},{"key":"267_CR176","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nbd.2016.05.008","volume":"97","author":"H Tanila","year":"2017","unstructured":"Tanila H (2017) The role of BDNF in Alzheimer\u2019s disease. Neurobiol Dis 97:114\u2013118. https:\/\/doi.org\/10.1016\/j.nbd.2016.05.008","journal-title":"Neurobiol Dis"},{"issue":"10","key":"267_CR177","doi-asserted-by":"publisher","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","volume":"2","author":"RE Tanzi","year":"2012","unstructured":"Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2(10):a006296. https:\/\/doi.org\/10.1101\/cshperspect.a006296","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"267_CR178","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pharmthera.2011.12.002","volume":"134","author":"HO Tayeb","year":"2012","unstructured":"Tayeb HO, Yang HD, Price BH, Tarazi FI (2012) Pharmacotherapies for Alzheimer\u2019s disease: beyond cholinesterase inhibitors. Pharmacol Ther 134(1):8\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.12.002","journal-title":"Pharmacol Ther"},{"issue":"3","key":"267_CR179","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jalz.2016.06.2362","volume":"13","author":"P Theofilas","year":"2017","unstructured":"Theofilas P, Ehrenberg AJ, Dunlop S, Di Lorenzo Alho AT, Nguy A, Leite REP, Rodriguez RD, Mejia MB, Suemoto CK, Ferretti-Rebustini REDL, Polichiso L, Nascimento CF, Seeley WW, Nitrini R, Pasqualucci CA, Jacob Filho W, Rueb U, Neuhaus J, Heinsen H, Grinberg LT (2017) Locus coeruleus volume and cell population changes during Alzheimer\u2019s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement 13(3):236\u2013246. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.2362","journal-title":"Alzheimers Dement"},{"issue":"5","key":"267_CR180","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/mp.2011.81","volume":"17","author":"D Tomasi","year":"2012","unstructured":"Tomasi D, Volkow ND (2012) Aging and functional brain networks. Mol Psychiatry 17(5):549\u2013558. https:\/\/doi.org\/10.1038\/mp.2011.81","journal-title":"Mol Psychiatry"},{"issue":"1","key":"267_CR181","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14737175.2017.1244482","volume":"17","author":"A Tramutola","year":"2017","unstructured":"Tramutola A, Lanzillotta C, Domenico FD (2017) Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. Expert Rev Neurother 17(1):33\u201345. https:\/\/doi.org\/10.1080\/14737175.2017.1244482","journal-title":"Expert Rev Neurother"},{"key":"267_CR182","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.arr.2015.08.006","volume":"24","author":"D Tromp","year":"2015","unstructured":"Tromp D, Dufour A, Lithfous S, Pebayle T, Despr\u00e9s O (2015) Episodic memory in normal aging and Alzheimer disease: insights from imaging and behavioral studies. Ageing Res Rev 24:232\u2013262. https:\/\/doi.org\/10.1016\/j.arr.2015.08.006","journal-title":"Ageing Res Rev"},{"issue":"12","key":"267_CR183","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s11064-020-03153-5","volume":"45","author":"AS Tsybko","year":"2020","unstructured":"Tsybko AS, Ilchibaeva TV, Filimonova EA, Eremin DV, Popova NK, Naumenko VS (2020) The chronic treatment with 5-HT2A receptor agonists affects the behavior and the BDNF system in mice. Neurochem Res 45(12):3059\u20133075. https:\/\/doi.org\/10.1007\/s11064-020-03153-5","journal-title":"Neurochem Res"},{"key":"267_CR184","doi-asserted-by":"publisher","unstructured":"Vann Jones SA, O\u2019Kelly A (2020) Psychedelics as a treatment for Alzheimer\u2019s disease dementia. Front Synapt Neurosci 12. https:\/\/doi.org\/10.3389\/fnsyn.2020.00034","DOI":"10.3389\/fnsyn.2020.00034"},{"issue":"4","key":"267_CR185","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","volume":"24","author":"J Versijpt","year":"2003","unstructured":"Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, Goethals I, Audenaert K, Slegers G, Dierckx RA, Korf J (2003) Imaging of the 5-HT2A system: age-, gender-, and Alzheimer\u2019s disease-related findings. Neurobiol Aging 24(4):553\u2013561. https:\/\/doi.org\/10.1016\/S0197-4580(02)00137-9","journal-title":"Neurobiol Aging"},{"key":"267_CR186","doi-asserted-by":"publisher","unstructured":"Wang W-Y, Tan M-S, Yu J-T, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease. Ann Transl Med 3(10). https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.49","DOI":"10.3978\/j.issn.2305-5839.2015.03.49"},{"issue":"5","key":"267_CR187","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol 57(5):520\u2013564. https:\/\/doi.org\/10.1177\/0022167817709585","journal-title":"J Humanist Psychol"},{"issue":"4","key":"267_CR188","doi-asserted-by":"publisher","first-page":"a006171","DOI":"10.1101\/cshperspect.a006171","volume":"2","author":"S Weintraub","year":"2012","unstructured":"Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2(4):a006171. https:\/\/doi.org\/10.1101\/cshperspect.a006171","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"267_CR189","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1523\/JNEUROSCI.22-07-02843.2002","volume":"22","author":"GV Williams","year":"2002","unstructured":"Williams GV, Rao SG, Goldman-Rakic PS (2002) The physiological role of 5-HT2A receptors in working memory. J Neurosci 22(7):2843\u20132854. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-07-02843.2002","journal-title":"J Neurosci"},{"issue":"3","key":"267_CR190","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/joim.12167","volume":"275","author":"A Wimo","year":"2014","unstructured":"Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M (2014) Health economic evaluation of treatments for Alzheimer\u2032s disease: impact of new diagnostic criteria. J Intern Med 275(3):304\u2013316. https:\/\/doi.org\/10.1111\/joim.12167","journal-title":"J Intern Med"},{"issue":"1","key":"267_CR191","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0269881106065859","volume":"21","author":"M Wittmann","year":"2007","unstructured":"Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21(1):50\u201364. https:\/\/doi.org\/10.1177\/0269881106065859","journal-title":"J Psychopharmacol"},{"issue":"2","key":"267_CR192","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR (2021) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci 4(2):568\u2013572. https:\/\/doi.org\/10.1021\/acsptsci.0c00194","journal-title":"ACS Pharmacol Transl Sci"},{"key":"267_CR193","doi-asserted-by":"publisher","unstructured":"Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (2008) Serotonin 5-HT2A receptor activation suppresses TNF-\u03b1-induced inflammation with extraordinary potency. J Pharmacol Exp Ther. https:\/\/doi.org\/10.1124\/jpet.108.143461","DOI":"10.1124\/jpet.108.143461"},{"issue":"5","key":"267_CR194","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jnc.15260","volume":"156","author":"CM Yuede","year":"2021","unstructured":"Yuede CM, Wallace CE, Davis TA, Gardiner WD, Hettinger JC, Edwards HM, Hendrix RD, Doherty BM, Yuede KM, Burstein ES, Cirrito JR (2021) Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses A\u03b2 production and related pathology in a mouse model of Alzheimer\u2019s disease. J Neurochem 156(5):658\u2013673. https:\/\/doi.org\/10.1111\/jnc.15260","journal-title":"J Neurochem"},{"issue":"1","key":"267_CR195","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1038\/srep07130","volume":"4","author":"D Yuki","year":"2014","unstructured":"Yuki D, Sugiura Y, Zaima N, Akatsu H, Takei S, Yao I, Maesako M, Kinoshita A, Yamamoto T, Kon R, Sugiyama K, Setou M (2014) DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer\u2019s disease. Sci Rep 4(1):7130. https:\/\/doi.org\/10.1038\/srep07130","journal-title":"Sci Rep"},{"key":"267_CR196","first-page":"225","volume":"6","author":"G Zhang","year":"2015","unstructured":"Zhang G, Stackman RW Jr (2015) The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 6:225","journal-title":"Front Pharmacol"},{"key":"267_CR197","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","volume":"64","author":"G Zhang","year":"2013","unstructured":"Zhang G, \u00c1sgeirsd\u00f3ttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW (2013) Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice. Neuropharmacology 64:403\u2013413. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.007","journal-title":"Neuropharmacology"},{"key":"267_CR198","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuropharm.2016.04.033","volume":"109","author":"G Zhang","year":"2016","unstructured":"Zhang G, Cinalli D, Cohen SJ, Knapp KD, Rios LM, Mart\u00ednez-Hern\u00e1ndez J, Luj\u00e1n R, Stackman RW (2016) Examination of the hippocampal contribution to serotonin 5-HT2A receptor-mediated facilitation of object memory in C57BL\/6J mice. Neuropharmacology 109:332\u2013340. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.04.033","journal-title":"Neuropharmacology"},{"key":"267_CR199","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"Q-F Zhao","year":"2016","unstructured":"Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, Xu W, Li J-Q, Wang J, Lai T-J, Yu J-T (2016) The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord 190:264\u2013271. https:\/\/doi.org\/10.1016\/j.jad.2015.09.069","journal-title":"J Affect Disord"},{"issue":"7","key":"267_CR200","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.biopsych.2014.01.020","volume":"75","author":"J Zhou","year":"2014","unstructured":"Zhou J, Seeley WW (2014) Network dysfunction in Alzheimer\u2019s disease and frontotemporal dementia: implications for psychiatry. Biol Psychiatry 75(7):565\u2013573. https:\/\/doi.org\/10.1016\/j.biopsych.2014.01.020","journal-title":"Biol Psychiatry"},{"issue":"1","key":"267_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt24","volume":"2","author":"E Zotova","year":"2010","unstructured":"Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D (2010) Inflammation in Alzheimer\u2019s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2(1):1. https:\/\/doi.org\/10.1186\/alzrt24","journal-title":"Alzheimers Res Ther"}],"container-title":["Current Topics in Behavioral Neurosciences","Disruptive Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2021_267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T20:07:14Z","timestamp":1661458034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2021_267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031121838","9783031121845"],"references-count":200,"URL":"https:\/\/doi.org\/10.1007\/7854_2021_267","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"4 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}